{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:30:15Z","timestamp":1791819015834,"version":"4.3.4"},"reference-count":32,"publisher":"Begell House","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Immunol"],"published-print":{"date-parts":[[2025]]},"abstract":"<p>This study aims to explore the relationship between tumor size, lymph node status, and ER\/PR\/HER2 expression in breast cancer patients. A total of 117 breast cancer patients who underwent surgery at our hospital were selected as the research objects. All patients underwent ipsilateral axillary lymph node dissection or sentinel lymph node biopsy during surgery. Pathological data and ultrasound features of primary lesions were collected. Univariate and multivariate logistic regression analyses were performed to evaluate the relationship between tumor size, lymph node status, and ER\/PR\/HER2 expression, as well as to identify the risk factors for lymph node metastasis in breast cancer patients. Among the 117 patients, 48 were positive for ipsilateral axillary lymph node metastasis and 69 were negative. Univariate analysis showed no significant correlation between age, PR status, molecular subtype, and lymph node metastasis (&lt;i&gt;P&lt;\/i&gt; &amp;#62; 0.05). Univariate analysis showed that tumor size, pathological type, menopausal status, Ki67 expression, HER2 status, and ER status were significantly associated with lymph node metastasis (&lt;i&gt;P&lt;\/i&gt; &amp;#60; 0.05). Logistic regression further identified tumor size &amp;#91;odds ratio (OR) &amp;#61; 1.809, 95&amp;#37; confidence interval (CI): 1.075-3.428, &lt;i&gt;P&lt;\/i&gt; &amp;#61; 0.018), pathological type (OR &amp;#61; 2.947, 95&amp;#37; CI: 1.241-7.536, &lt;i&gt;P&lt;\/i&gt; &amp;#61; 0.012), Ki67 expression (OR &amp;#61; 15.923, 95&amp;#37; CI: 3.219-74.512, &lt;i&gt;P&lt;\/i&gt; &amp;#61; 0.001), HER2 status (OR &amp;#61; 2.509, 95&amp;#37; CI: 1.586-5.769, &lt;i&gt;P&lt;\/i&gt; &amp;#61; 0.015), and ER status (OR &amp;#61; 3.226, 95&amp;#37; CI: 1.408-8.277, &lt;i&gt;P&lt;\/i&gt; &amp;#61; 0.007) as independent risk factors for lymph node metastasis. This study reveals that lymph node metastasis in breast cancer patients is significantly associated with larger tumor size (&amp;#62; 20 mm), invasive tumor type, higher Ki67 expression, HER2 positivity, and ER negativity. These findings emphasize the importance of incorporating these risk factors into clinical assessments to guide individualized treatment planning. By identifying patients with elevated lymph node metastasis risk, clinicians can better tailor treatment strategies to improve patient outcomes and optimize therapeutic interventions.\n<\/p>","DOI":"10.1615\/critrevimmunol.2025055318","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T16:22:11Z","timestamp":1736526131000},"page":"1-9","source":"Crossref","is-referenced-by-count":4,"title":["Assessing the Relationship among Tumor Size, Lymph Node Status, and ER\/PR\/HER2 Expression in Patients with Breast Cancer"],"prefix":"10.1615","volume":"45","author":[{"given":"Liqin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanfan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"Coughlin SS. Epidemiology of breast cancer in women. Adv Exp Med Biol. 2019;1152:9-29.","DOI":"10.1007\/978-3-030-20301-6_2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Winters S, Martin C, Murphy D, Shokar NK. Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 2017;151:1-32.","DOI":"10.1016\/bs.pmbts.2017.07.002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Jafari SH, Saadatpour Z, Salmaninejad A, Momeni F, Mokhtari M, Nahand JS, Rahmati M, Mirzaei H, Kianmehr M. Breast cancer diagnosis: Imaging techniques and biochemical markers. J Cell Physiol. 2018;233(7):5200-13.","DOI":"10.1002\/jcp.26379"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Autenshlyus A, Davletova K, Varaksin N, Marinkin I, Lyakhovich V. Cytokines in various molecular subtypes of breast cancer. Int J Immunopathol Pharmacol. 2021;35:20587384211034089.","DOI":"10.1177\/20587384211034089"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Hashmi AA, Bukhari U, Najam J, Dowlah T, Ali AH, Diwan MA, Anjali F, Sham S, Zia S, Irfan M. Luminal B, Human epidermal crowth factor receptor 2 (HER2\/neu), and triple-negative breast cancers associated with a better chemotherapy response than luminal a breast cancers in postneoadjuvant settings. Cureus. 2023;15(6):e40066.","DOI":"10.7759\/cureus.40066"},{"key":"7","unstructured":"Hassan WA, El-Assmy M, ElBanna AK, Harbieh I, Noufal N, Lotfy H, Shemais TAH, Haikal OA, Saber MM, Ali RI. Associations between BCL-2 expression and different histopathological prognostic factors in different molecular subtypes of invasive breast carcinoma of no special type. Histol Histopathol. 2024:18831."},{"key":"8","doi-asserted-by":"crossref","unstructured":"Radhakrishnan N, Mathews A, Rajeev KR, Nair PS, Bhargavan R, Viswanathan AJ. Molecular subtypes of invasive breast carcinoma of no special type, their correlation with histopathological features, Ki 67 index and tumor budding: A retrospective comparative study. Indian J Pathol Microbiol. 2022;65(4):772-80.","DOI":"10.4103\/ijpm.ijpm_90_21"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Yao Q, Hou W, Wu K, Bai Y, Long M, Diao X, Jia L, Niu D, Li X. Using whole slide gray value map to predict HER2 expression and FISH status in breast cancer. Cancers. 2022;14(24):6233.","DOI":"10.3390\/cancers14246233"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Merino Bonilla JA, Torres Tabanera M, Ros Mendoza LH. Breast cancer in the 21st century: From early detection to new therapies. Radiologia. 2017;59(5):368-79.","DOI":"10.1016\/j.rxeng.2017.08.001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Thorat MA, Balasubramanian R. Breast cancer prevention in high-risk women. Best Pract Res Clin Obstet Gynaecol. 2020;65:18-31.","DOI":"10.1016\/j.bpobgyn.2019.11.006"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Nagini S. Breast cancer: Current molecular therapeutic targets and new players. Anticancer Agents Med Chem. 2017;17(2):152-63.","DOI":"10.2174\/1871520616666160502122724"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Rossi L, Mazzara C, Pagani O. Diagnosis and treatment of breast cancer in young women. Curr Treat Options Oncol. 2019;20(12):86.","DOI":"10.1007\/s11864-019-0685-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033.","DOI":"10.1259\/bjr.20211033"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Marino MA, Avendano D, Zapata P, Riedl CC, Pinker K. Lymph node imaging in patients with primary breast cancer: Concurrent diagnostic tools. Oncologist. 2020;25(2):e231-42.","DOI":"10.1634\/theoncologist.2019-0427"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Chung HL, Le-Petross HT, Leung JWT. Imaging updates to breast cancer lymph node management. Radiographics. 2021;41(5):1283-99.","DOI":"10.1148\/rg.2021210053"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Song BI. A machine learning-based radiomics model for the prediction of axillary lymph-node metastasis in breast cancer. Breast Cancer. 2021;28(3):664-71.","DOI":"10.1007\/s12282-020-01202-z"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Min Y, Liu X, Hu D, Chen H, Chen J, Xiang K, Yin G, Han Y, Feng Y, Luo H. Risk factors, prognostic factors, and nomogram for distant metastasis in breast cancer patients without lymph node metastasis. Front Endocrinol. 2021;12:771226.","DOI":"10.3389\/fendo.2021.771226"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Wang W, Qiu P, Li J. Internal mammary lymph node metastasis in breast cancer patients based on anatomical imaging and functional imaging. Breast Cancer. 2022;29(6):933-44.","DOI":"10.1007\/s12282-022-01377-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Zhao R, Jiang H, Cao J, Li B, Xu L, Dai S. Prediction of axillary lymph node metastasis in invasive breast cancer by sound touch elastography. Ultrasound Med Biol. 2022;48(9):1879-87.","DOI":"10.1016\/j.ultrasmedbio.2022.05.018"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Elshanbary AA, Awad AA, Abdelsalam A, Ibrahim IH, Abdel-Aziz W, Darwish YB, Isa AS, Drid B, Mustafa MG, Allam RH, Abo Ali AA, Nourelden AZ, Ragab KM, AlGwaiz HIM, Awaji AA, Germoush MO, Albrakati A, Piscopo M, Ghaboura N, Zaazouee MS. The diagnostic accuracy of intraoperative frozen section biopsy for diagnosis of sentinel lymph node metastasis in breast cancer patients: a meta-analysis. Environ Sci Pollut Res Int. 2022;29(32):47931-41.","DOI":"10.1007\/s11356-022-20569-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Hou Q, Chen S, An Q, Li B, Fu Y, Luo Y. Extracellular Hsp90alpha promotes tumor lymphangiogenesis and lymph node metastasis in breast cancer. Int J Mol Sci. 2021;22(14):7747.","DOI":"10.3390\/ijms22147747"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Hermansyah D, Indra W, Paramita DA, Siregar ES. Role of hormonal receptor in predicting sentinel lymph node metastasis in early breast cancer. Med Arch. 2022;76(1):34-8.","DOI":"10.5455\/medarh.2022.76.34-38"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Chang JM, Leung JWT, Moy L, Ha SM, Moon WK. Axillary nodal evaluation in breast cancer: State of the art. Radiology. 2020;295(3):500-15.","DOI":"10.1148\/radiol.2020192534"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Zhang S, Zhang D, Yi S, Gong M, Lu C, Cai Y, Tang X, Zou L. The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: A systematic review and meta-analysis. Oncotarget. 2017;8(2):2863-73.","DOI":"10.18632\/oncotarget.13752"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Fu X, Jiang B, Fu J, Jia J. MRI diagnosis and pathological examination of axillary lymph node metastasis in breast cancer patients. Contrast Media Mol Imaging. 2022;2022:4519982.","DOI":"10.1155\/2022\/4519982"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Yao ZX, Lu LJ, Wang RJ, Jin LB, Liu SC, Li HY, Ren GS, Wu KN, Wang DL, Kong LQ. Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. Med Oncol. 2014;31(1):798.","DOI":"10.1007\/s12032-013-0798-y"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Chen H, Meng X, Hao X, Li Q, Tian L, Qiu Y, Chen Y. Correlation analysis of pathological features and axillary lymph node metastasis in patients with invasive breast cancer. J Immunol Res. 2022;2022:7150304.","DOI":"10.1155\/2022\/7150304"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Dihge L, Vallon-Christersson J, Hegardt C, Saal LH, Hakkinen J, Larsson C, Ehinger A, Loman N, Malmberg M, Bendahl PO, Borg A, Staaf J, Ryden L. Prediction of lymph node metastasis in breast cancer by gene expression and clinicopathological models: Development and validation within a population-based cohort. Clin Cancer Res. 2019;25(21):6368-81.","DOI":"10.1158\/1078-0432.CCR-19-0075"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Okuno J, Miyake T, Sota Y, Tanei T, Kagara N, Naoi Y, Shimoda M, Shimazu K, Kim SJ, Noguchi S. Development of prediction model including MicroRNA expression for sentinel lymph node metastasis in ER-positive and HER2-negative breast cancer. Ann Surg Oncol. 2021;28(1):310-9.","DOI":"10.1245\/s10434-020-08735-9"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Eric I, Petek Eric A, Kristek J, Koprivcic I, Babic M. Breast cancer in young women: Pathologic and immunohistochemical features. Acta Clin Croat. 2018;57(3):497-502.","DOI":"10.20471\/acc.2018.57.03.13"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Pang L, Li Y, Sun D. Effect of recombinant human adenovirus type 5 injection combined with haploidentical natural killer cell immunotherapy on immune function and adverse reactions in patients with malignant ascites caused by ovarian cancer. J Mod Med Oncol. 2021. doi: 10.53964\/jmmo.2021001.","DOI":"10.53964\/jmmo.2021001"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Sharma BK. Prospective paradigms in therapeutic modalities in the management of human cutaneous melanoma: Plausible role of bioactive compounds. J Mod Med Oncol. 2022. doi: 10.53964\/jmmo. 2022001.","DOI":"10.53964\/jmmo"}],"container-title":["Critical Reviews in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/210eafda356ca0c1\/CRI-55318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T05:42:15Z","timestamp":1750657335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/2ff21abf44b19838,3e5b3af60141eb55,210eafda356ca0c1.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevimmunol.2025055318","relation":{},"ISSN":["1040-8401"],"issn-type":[{"value":"1040-8401","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}